B+
Bull case
30%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
BDTX
Black Diamond TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The reported NSCLC activity and CNS responses could support a differentiated pivotal program if durability holds and FDA feedback is constructive. Q4 milestones provide a near-term test [#SEC-8K-2026-08-05].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical-stage losses and rising development spending could shorten the stated cash runway or eventually require financing [#SEC-8K-2026-08-05].
Momentum
77
Value
44
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.85 · Bull $2.60 · Bear $0.90Analysis 2026-10-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum77 · Δ7d -
Value44 · Δ7d -0.0
Sentiment64 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Clinical-stage losses and rising development spending could shorten the stated cash runway or eventually require financing [#SEC-8K-2026-08-05].
- • GBM randomized-phase initiation may slip, and clinical benefit has not yet been demonstrated in that study [#SEC-8K-2026-08-05].
- • The evidence remains early and single-arm, with limited patient numbers; a less favorable pivotal path, weaker follow-up, or GBM enrollment delay could materially impair the thesis.
Catalyst clock
2026-12-31
Q4 silevertinib NSCLC update and FDA feedback
Lead driver: Sentiment · See AI snapshot
Momentum
77
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
64
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 77.0 / Value 43.7 / Sentiment 64.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-14. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.85
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$97.1M
Beta
3.37
Shares Out
57.45M
P/E (TTM)
7.1
P/S (TTM)
2.09
P/FCF (TTM)
6.86
Rev YoY
-100.0%
EPS YoY
-7.1%
Gross Margin
+99.5%
Op Margin
+16.9%
Net Debt
-$109.87M
Current Ratio
7.28
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data